AlphAIAlphAI — Financial news for AI agents
en.sedaily.comNOV 32 min read$TEVA

Samsung Bioepis Signs Up to $420 Million U.S. Biosimilar Deal With Teva

Samsung Bioepis and Teva agreed to a $420M deal for U.S. commercialization of two biosimilars (Renflexis, Eticovo) for autoimmune diseases. Samsung handles development and manufacturing, Teva manages sales. The deal includes upfront payments, milestones, and royalties.

Original reporting
en.sedaily.com
Published Nov 3, 2026, 8:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Samsung Bioepis Signs Up to $420 Million U.S. Biosimilar Deal With Teva — source image
Source · en.sedaily.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The agreement provides Teva with two additional FDA‑approved biosimilars, expanding its product pipeline and potential royalty income.

02

Market read

A sizable $420 M deal that could lift Teva's earnings outlook and signal continued consolidation in the biosimilar space.

03

What to watch

Regulatory or reimbursement hurdles for the biosimilars could delay revenue realization.

Relevance 8/10Novelty 8/10Timing: announcement day

Background

Samsung Bioepis, a joint venture of Samsung and Biogen, partners with Teva to commercialize Renflexis and Eticovo in the U.S.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva announced a $420 million U.S. commercialization agreement with Samsung Bioepis for two biosimilars.

Expected impact

likely modest upside as the market prices in additional sales and royalty streams

Evidence & confidence

Teva will handle U.S. sales and share profits, providing near‑term revenue and long‑term royalty upside; the upfront payment and milestones are material for a mid‑cap pharma.

Market effects

Sector

strengthens the U.S. biosimilar market and may pressure competitors' pricing.

Regional

boosts South Korean biotech export visibility and supports U.S. specialty pharma growth.

Global

adds to global consolidation trends in biologics and could influence other biosimilar partnerships.

Counterpoint

What could challenge this read

The profit‑share model may limit Teva's upside if launch milestones are not met, weighing on the stock.

Key entities

  • company
    Samsung Bioepis

    Joint venture developing and supplying the biosimilars.

  • company
    Teva Pharmaceuticals International

    U.S. sales and commercialization partner.

Read at source← All news

StoryTeva secures U.S. rights to two Samsung Bioepis biosimilars

Also covered by

1 outlet

Related articles

NOV 3
$TEVAMed

Teva Pharmaceutical Industries Ltd: Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva Pharmaceutical and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S. Teva will obtain rights to ETICOVO upon close and infliximab-abda in Q3 2027. The deal expands Teva's biosimilars portfolio as part of its Pivot to Growth strategy. Samsung Bioepis will retain regulatory and manufacturing responsibilities. Financial terms include an upfront payment and potential milestone payments.

finanznachrichten.de2 min
NOV 3
$TEVAMed

Teva signs deal for two FDA-approved biosimilars

Teva Pharmaceutical (TEVA) signed a deal with Samsung Bioepis to commercialize two FDA-approved biosimilars, ETICOVO and infliximab-abda, in the U.S. Teva will gain rights to ETICOVO at closing and infliximab-abda in Q3 2027, with the transaction expected to close by late 2026. Teva will make payments over three years and potentially additional milestone payments.

grafa.com2 min
NOV 3
$TEVAMed

Teva to halt Phase II MSA therapy trial after futility analysis

Teva Pharmaceuticals halted a Phase II trial for emrusolmin (TEV-‘286) to treat multiple system atrophy (MSA) after an interim analysis suggested it would not meet its primary efficacy endpoint. The decision followed a recommendation from the independent data monitoring committee (IDMC), which found a low probability of demonstrating efficacy. No safety concerns were raised. Teva is developing the therapy in collaboration with privately managed biotechnology company MODAG.

clinicaltrialsarena.com4 min
NOV 3
$TEVAMed

Samsung Bioepis teams with Teva to sell two US biosimilars

Samsung Bioepis (0126Z0) and Teva Pharmaceuticals agreed to commercialize two biosimilars in the U.S. Samsung Bioepis will handle development and supply, while Teva manages sales. The deal is valued at up to $420 million, including upfront and milestone payments. The biosimilars, Renflexis and Eticovo, treat autoimmune diseases and have FDA approval.

biz.chosun.com2 min